Nasonex (Mometasone Furoate)

• Nasonex (mometasone furoate) is a nasal corticosteroid used to manage inflammatory conditions of the nasal passages.
• Allergic rhinitis (perennial): reduces nasal congestion, itching and sneezing.
• Seasonal allergic rhinitis: controls symptoms triggered by seasonal allergens.
• Nasal polyps: decreases polyp size and improves nasal airflow.

• Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, modulating gene transcription to suppress pro‑inflammatory cytokines, reduce vascular permeability, and inhibit leukocyte migration. This anti‑inflammatory activity diminishes edema and mucus production, restoring normal nasal airflow.

Nasonex may cause a range of local and systemic adverse reactions.

Common Side Effects

• Nasal irritation or burning sensation
• Headache
• Epistaxis (nosebleeds)
• Throat irritation or dryness
• Cough
• Altered taste or odor perception

Serious or Rare Side Effects

• Adrenal suppression with prolonged high‑dose use
• Glaucoma or cataract formation
• Severe or persistent nosebleeds
• Opportunistic fungal infection of the nasal passages
• Systemic immunosuppression leading to increased infection risk
• Hypersensitivity reactions such as angioedema

• Before using Nasonex, consider the following safety measures.
• Prescribe only as directed: follow the healthcare professional’s instructions for frequency and duration.
• Avoid in hypersensitivity: do not use if the patient has known allergy to mometasone furoate or any component of the formulation.
• Caution after nasal surgery or trauma: defer use until healing is complete to reduce risk of bleeding.
• Monitor for adrenal effects: prolonged high‑dose therapy may affect endogenous cortisol production.
• Use with care in glaucoma or cataract patients: intra‑ocular pressure should be monitored.
• Store at room temperature: keep in the original container, protect from moisture and direct heat.

Mometasone furoate can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase systemic exposure.
• Concurrent intranasal corticosteroids can raise the risk of systemic glucocorticoid effects.
• Systemic immunosuppressants may amplify infection risk when combined.

Moderate Interactions (Monitor Closely)

• Systemic corticosteroids may add to overall glucocorticoid load.
• Live vaccines may have reduced efficacy; timing should be coordinated.
• Antifungal agents metabolized by CYP3A4 may require monitoring of levels.